Oncology: Basic & Translational -> Basic Science (O) 34

34 - Self-Assembling and DisAssembling Bispecific Antibodies for Curative 2-step Pretargeted Radioimmunotherapy (ID 13)

Session Name
Center for Therapy Excellence YIA Symposium
Speakers
Authors
Presentation Topic
Oncology: Basic & Translational -> Basic Science (O)
Presentation Number
34

Previous Eposter
33 - Improving Efficiency of Radium-223 via Pharmacological Blockade of Gastrointestinal Uptake and Increase Bone targeting (ID 12)

Next Eposters
35 - FLT-PET to evaluate sequencing of chemotherapies to enhance efficacy of treatment in triple negative breast cancers (ID 15)
36 - Low-dose TRT reshapes the microenvironment of prostate tumors to potentiate response to immunotherapy (ID 14)
37 - Factors predicting metastatic disease in 68Ga-PSMA-11 PET positive osseous lesions in prostate cancer (ID 1231)
38 - Diagnostic Performance of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the Phase 3, Multicenter CONDOR Study (ID 1227)
39 - Survey by the French Medicine Agency (ANSM) of the practice, result and impact of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer with non-contributive 18F-fluorocholine PET/CT: 1177 examinations (ID 1234)
40 - Preliminary results of a prospective, multicenter trial assessing the impact of 18F-DCFPyL-PET/CT on the management of patients with recurrent prostate cancer. (ID 1228)
41 - Incidence of local prostate cancer recurrence by 68Ga-PSMA-11 PET/CT is higher after definitive Radiation Therapy than after Radical Prostatectomy: a single center post-hoc retrospective analysis of recurrence patterns of 787 patients. (ID 1233)
42 - Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrent prostate cancer (ID 1229)
43 - Impact of68Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial (ID 1232)
44 - Combined value of PSMA-based 18F-DCFPyL, 18F-FDG and 18F-NaF PET/CT imaging in metastatic prostate cancer patients (ID 1230)